DeepMed Research

Nanfang Hospital Southern Medical University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

Recruiting

Conditions: Immunotherapy
Hyperprogression
Biomarker

First Posted Date: 2024-02-23

Last Posted Date: 2024-03-15

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 374

Registration Number: NCT06276088

Locations: 🇨🇳
Jieyang people's hospital, Jieyang, China
🇨🇳
Huizhou Central People's Hospital, Huizhou, China
🇨🇳
Meizhou People's Hospital, Meizhou Academy of Medical Sciences Meizhou, Meizhou, China

and more 2 locations

Improvement of Depression With Use of ATP

Not Applicable

Recruiting

Conditions: Depression

Interventions: Drug: ATP Group
Drug: Placebo Group

First Posted Date: 2024-02-20

Last Posted Date: 2024-03-19

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 120

Registration Number: NCT06266715

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

Recruiting

Conditions: Non-small Cell Lung Cancer

First Posted Date: 2024-01-30

Last Posted Date: 2024-01-30

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 108

Registration Number: NCT06232265

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Phase 2

Recruiting

Conditions: IKZF1 Gene Mutation
Acute Lymphoblastic Leukemia
Philadelphia-Positive ALL
Philadelphia Chromosome
Adult ALL

Interventions: Drug: Prednisone, Olverembatinib, Blinatumomab, Chidamide

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 67

Registration Number: NCT06220487

Locations: 🇨🇳
Dept of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

TIPS for PH Patients: an Observational, Cohort Study

Recruiting

Conditions: Cirrhosis Portal

Interventions: Other: No intervention, observational study

First Posted Date: 2024-01-24

Last Posted Date: 2024-01-24

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 300

Registration Number: NCT06221982

Locations: 🇨🇳
Nanfang hospital, Southern Medical Uiversity, Guangzhou, Guangdong, China

A Computer-aided (CADx）System in Real-time Characterization of Colorectal Ulcerative Diseases

Recruiting

Conditions: Colorectal Ulcers
Computer-aided System

Interventions: Diagnostic Test: Colonoscopy images and videos

First Posted Date: 2024-01-17

Last Posted Date: 2024-01-17

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 1000

Registration Number: NCT06208982

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Undefined, China

Accuracy of Computer-aided (CADx) System in Real-time Characterization of Colorectal Ulcerative Diseases

Not yet recruiting

Conditions: Colorectal Ulcers
Computer-aided System

Interventions: Diagnostic Test: Test images and videos

First Posted Date: 2024-01-17

Last Posted Date: 2024-01-17

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 495

Registration Number: NCT06207825

Tongyuan Acupuncture on Consciousness Disorder After Stroke

Not Applicable

Recruiting

Conditions: Stroke

Interventions: Device: Needles that are not on acupoints
Device: Acupuncture with regulating immunity as the core of treatment

First Posted Date: 2024-01-12

Last Posted Date: 2024-03-21

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 174

Registration Number: NCT06202833

Locations: 🇨🇳
YI WEI, Guangzhou, Guangdong, China

Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore

Phase 2

Not yet recruiting

Conditions: Gastric Cancer

Interventions: Drug: Cadonilimab plus CapeOX chemotherapy

First Posted Date: 2024-01-11

Last Posted Date: 2024-03-25

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 50

Registration Number: NCT06202716

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients

Not Applicable

Recruiting

Conditions: Glioma, Malignant

Interventions: Drug: Rivaroxaban 10 MG
Drug: Placebo

First Posted Date: 2024-01-09

Last Posted Date: 2024-01-09

Lead Sponsor: Nanfang Hospital, Southern Medical University

Target Recruit Count: 320

Registration Number: NCT06196918

Locations: 🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China
🇨🇳
Beijing Tiantan Hospital, Beijing, Beijing, China
🇨🇳
Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy